Orbifloxacin is a fluoroquinolone drug used widely in companion animal medicine. At twice the MIC, the PAEs (post-antibiotic effects) of orbifloxacin ranged from -0.28-0.93 h (mean, 0.29 h) for E. coli and -0.18-1.18 h (mean, 0.37 h) for P. aeruginosa[2]. Orbifloxacin could have success against susceptible mastitis pathogens in goats[3]. Oral ORB (Orbifloxacin, 2.5 mg/kg and 5 mg/kg) may alter the total counts and composition of fecal coliform, but is unlikely to yield highly fluoroquinolone-resistant mutants of E. coli and C. freundii in cats, possibly because of the high drug concentration in feces[4]. In addition, orbifloxacin was an effective, safe, and convenient antibiotic for the treatment of superficial and deep staphylococcal pyoderma in dogs[5]. Orbifloxacin and the peptide AK15 possess significant bactericidal activity against Mycobacterium tuberculosis (Mtb) in vitro. Orbifloxacin also showed an effective ability on the clearance of intracellular Mtb and protect mice from a strong inflammatory response but not AK15[6].
搜索
